Michael F. Mahoney's most recent trade in Boston Scientific Corp. was a trade of 186,240 Common Stock done at an average price of $48.3 . Disclosure was reported to the exchange on Aug. 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Purchase of securities on an exchange or from another person at price $ 48.33 per share. | 03 Aug 2026 | 186,240 | 1,590,024 (0%) | 0% | 48.3 | 9,001,408 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 03 Aug 2026 | 22,119 | 22,119 (0%) | 0% | 48.4 | 1,071,223 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 28 May 2026 | 386,755 | 0 (0%) | 0% | 0 | Common Stock | |
| CVS Health | Mr. Michael F. Mahoney | Director | 14 May 2026 | 1,737 | 6,428 | - | - | Deferred Stock Units | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 132,190 | 1,551,003 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 132,190 | 1,683,193 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 132,190 | 1,551,003 (0%) | 0% | 0 | - | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 132,190 | 1,683,193 (0%) | 0% | 0 | - | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.73 per share. | 13 Feb 2026 | 132,099 | 1,559,926 (0%) | 0% | 74.7 | 9,871,758 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.73 per share. | 13 Feb 2026 | 132,099 | 1,559,926 (0%) | 0% | 74.7 | 9,871,758 | - |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 13 Feb 2026 | 16,524 | 16,524 | - | - | Restricted Stock Units | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 16,524 | 1,576,450 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 16,524 | 1,576,450 (0%) | 0% | 0 | - | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 13 Feb 2026 | 16,265 | 0 | - | - | Restricted Stock Units | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 16,265 | 1,584,725 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 16,265 | 1,584,725 (0%) | 0% | 0 | - | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 13 Feb 2026 | 8,832 | 26,498 | - | - | Restricted Stock Units | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 8,832 | 1,692,025 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 8,832 | 1,692,025 (0%) | 0% | 0 | - | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.73 per share. | 13 Feb 2026 | 7,990 | 1,568,460 (0%) | 0% | 74.7 | 597,093 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.73 per share. | 13 Feb 2026 | 7,990 | 1,568,460 (0%) | 0% | 74.7 | 597,093 | - |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.73 per share. | 13 Feb 2026 | 7,865 | 1,576,860 (0%) | 0% | 74.7 | 587,751 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.73 per share. | 13 Feb 2026 | 7,865 | 1,576,860 (0%) | 0% | 74.7 | 587,751 | - |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 12 Feb 2026 | 131,329 | 131,329 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 12 Feb 2026 | 55,652 | 55,652 | - | - | Restricted Stock Units | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 13,704 | 1,425,439 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 12 Feb 2026 | 13,704 | 27,408 | - | - | Restricted Stock Units | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 13,704 | 1,425,439 (0%) | 0% | 0 | - | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.12 per share. | 12 Feb 2026 | 6,626 | 1,418,813 (0%) | 0% | 74.1 | 491,119 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.12 per share. | 12 Feb 2026 | 6,626 | 1,418,813 (0%) | 0% | 74.1 | 491,119 | - |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 93.49 per share. | 02 Feb 2026 | 159,701 | 1,411,735 (0%) | 0% | 93.5 | 14,930,526 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 93.49 per share. | 02 Feb 2026 | 159,701 | 1,411,735 (0%) | 0% | 93.5 | 14,930,526 | - |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.55 per share. | 02 Feb 2026 | 49,407 | 1,526,289 (0%) | 0% | 24.6 | 1,212,942 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 02 Feb 2026 | 49,407 | 98,814 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.55 per share. | 02 Feb 2026 | 49,407 | 1,526,289 (0%) | 0% | 24.6 | 1,212,942 | - |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.09 per share. | 02 Feb 2026 | 46,347 | 1,572,636 (0%) | 0% | 27.1 | 1,255,540 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 02 Feb 2026 | 46,347 | 231,739 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.09 per share. | 02 Feb 2026 | 46,347 | 1,572,636 (0%) | 0% | 27.1 | 1,255,540 | - |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 94.06 per share. | 02 Feb 2026 | 1,200 | 1,571,436 (0%) | 0% | 94.1 | 112,868 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 94.06 per share. | 02 Feb 2026 | 1,200 | 1,571,436 (0%) | 0% | 94.1 | 112,868 | - |
| CVS Health | Mr. Michael F. Mahoney | Director | 20 Nov 2025 | 2,021 | 4,613 | - | - | Deferred Stock Units | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Oct 2025 | 149,992 | 213,679 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Oct 2025 | 88,197 | 289,675 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Oct 2025 | 73,996 | 363,671 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 103.39 per share. | 02 Jun 2025 | 89,921 | 1,476,882 (0%) | 0% | 103.4 | 9,296,950 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 104.05 per share. | 02 Jun 2025 | 74,522 | 1,566,803 (0%) | 0% | 104.1 | 7,754,186 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 02 Jun 2025 | 56,212 | 0 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.26 per share. | 02 Jun 2025 | 56,212 | 1,591,918 (0%) | 0% | 17.3 | 970,219 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 02 Jun 2025 | 49,407 | 148,221 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.55 per share. | 02 Jun 2025 | 49,407 | 1,641,325 (0%) | 0% | 24.6 | 1,212,942 | Common Stock |
| CVS Health | Mr. Michael F. Mahoney | Director | 15 May 2025 | 2,542 | 2,542 | - | - | Deferred Stock Units | ||
| CVS Health | Mr. Michael F. Mahoney | Director | Grant, award, or other acquisition of securities at price $ 60.47 per share. | 15 May 2025 | 144 | 6,345 (0%) | 0% | 60.5 | 8,708 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 102.13 per share. | 01 May 2025 | 91,282 | 1,535,706 (0%) | 0% | 102.1 | 9,322,266 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 102.92 per share. | 01 May 2025 | 73,161 | 1,626,988 (0%) | 0% | 102.9 | 7,529,708 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.26 per share. | 01 May 2025 | 56,212 | 1,650,742 (0%) | 0% | 17.3 | 970,219 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 01 May 2025 | 56,212 | 56,212 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.55 per share. | 01 May 2025 | 49,407 | 1,700,149 (0%) | 0% | 24.6 | 1,212,942 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 01 May 2025 | 49,407 | 197,628 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 100.01 per share. | 01 Apr 2025 | 164,442 | 1,594,530 (0%) | 0% | 100.0 | 16,445,072 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 01 Apr 2025 | 56,211 | 112,424 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.26 per share. | 01 Apr 2025 | 56,211 | 1,709,565 (0%) | 0% | 17.3 | 970,202 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 01 Apr 2025 | 49,407 | 247,035 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.55 per share. | 01 Apr 2025 | 49,407 | 1,758,972 (0%) | 0% | 24.6 | 1,212,942 | Common Stock |
| CVS Health | Mr. Michael F. Mahoney | Director | Purchase of securities on an exchange or from another person at price $ 66.70 per share. | 18 Feb 2025 | 30,000 | 39,356 (0%) | 0% | 66.7 | 2,001,000 | Common Stock (By Trust) |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 13 Feb 2025 | 90,915 | 90,915 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 13 Feb 2025 | 35,330 | 35,330 | - | - | Restricted Stock Units | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 13 Feb 2025 | 18,334 | 0 | - | - | Restricted Stock Units | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 18,334 | 1,662,219 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 16,524 | 1,643,475 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 13 Feb 2025 | 16,524 | 33,048 | - | - | Restricted Stock Units | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 13 Feb 2025 | 16,265 | 16,265 | - | - | Restricted Stock Units | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 16,265 | 1,651,750 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 106.11 per share. | 13 Feb 2025 | 8,865 | 1,653,354 (0%) | 0% | 106.1 | 940,665 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 106.11 per share. | 13 Feb 2025 | 7,990 | 1,635,485 (0%) | 0% | 106.1 | 847,819 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 106.11 per share. | 13 Feb 2025 | 7,865 | 1,643,885 (0%) | 0% | 106.1 | 834,555 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 12 Feb 2025 | 13,704 | 41,112 | - | - | Restricted Stock Units | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 13,704 | 1,633,577 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 105.77 per share. | 12 Feb 2025 | 6,626 | 1,626,951 (0%) | 0% | 105.8 | 700,832 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 130,118 | 1,682,788 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 105.98 per share. | 11 Feb 2025 | 62,915 | 1,619,873 (0%) | 0% | 106.0 | 6,667,732 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 01 Jan 2025 | 57,121 | 0 | - | - | Performance Share Units | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 57,121 | 1,578,326 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 89.32 per share. | 01 Jan 2025 | 25,656 | 1,552,670 (0%) | 0% | 89.3 | 2,291,594 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Nov 2024 | 7,800 | 201,478 (0%) | 0% | 0 | Common Stock | |
| CVS Health | Mr. Michael F. Mahoney | Director | Grant, award, or other acquisition of securities at price $ 57.10 per share. | 21 Nov 2024 | 2,200 | 6,201 (0%) | 0% | 57.1 | 125,620 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 84.74 per share. | 05 Nov 2024 | 160,182 | 1,521,205 (0%) | 0% | 84.7 | 13,573,743 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 05 Nov 2024 | 56,211 | 168,635 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.26 per share. | 05 Nov 2024 | 56,211 | 1,628,307 (0%) | 0% | 17.3 | 970,202 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 05 Nov 2024 | 55,676 | 0 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.31 per share. | 05 Nov 2024 | 55,676 | 1,683,983 (0%) | 0% | 16.3 | 908,076 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 85.17 per share. | 05 Nov 2024 | 2,596 | 1,681,387 (0%) | 0% | 85.2 | 221,108 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 84.94 per share. | 07 Oct 2024 | 82,085 | 1,572,096 (0%) | 0% | 84.9 | 6,972,431 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 84.31 per share. | 07 Oct 2024 | 80,692 | 1,654,181 (0%) | 0% | 84.3 | 6,803,360 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 07 Oct 2024 | 56,211 | 224,846 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.26 per share. | 07 Oct 2024 | 56,211 | 1,679,198 (0%) | 0% | 17.3 | 970,202 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 07 Oct 2024 | 55,675 | 55,676 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.31 per share. | 07 Oct 2024 | 55,675 | 1,734,873 (0%) | 0% | 16.3 | 908,059 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 81.17 per share. | 05 Sep 2024 | 162,777 | 1,622,987 (0%) | 0% | 81.2 | 13,212,544 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.26 per share. | 05 Sep 2024 | 56,211 | 1,730,089 (0%) | 0% | 17.3 | 970,202 | Common Stock |
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | 05 Sep 2024 | 56,211 | 281,057 | - | - | Stock Option (Right to Buy) | ||
| Boston Scientific | Mr. Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.31 per share. | 05 Sep 2024 | 55,675 | 1,785,764 (0%) | 0% | 16.3 | 908,059 | Common Stock |